Remove Clinic Remove Hospital Remove Manufacturing Remove Supply Chain
article thumbnail

9 Technologies That Will Shape The Future Of Dentistry

The Medical Futurist

Artificial intelligence Already, dentists employ software to get insights into clinical decision-making, but AI is changing the face of dentistry, just like it is in many other fields. But AR also found a home in dentistry for both educational and clinical purposes.

Patients 126
article thumbnail

The Wholesaling Prohibition (Potentially) Demystified? FDA’s Take on Supply Chains for Section 503B Outsourcing Facilities

FDA Law

Under section 503B, drugs compounded by an FDA-registered outsourcing facility under the supervision of a licensed pharmacist can qualify for exemptions from FDA approval, labeling with adequate directions for use, and certain drug supply chain security requirements, subject to specific conditions. See 21 U.S.C. Section II at 2.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

The Rising Tide of Medical Waste: One Model for Improvement

My Green Doctor

Dilating and anesthetic eye drops are used routinely to treat patients in most ophthalmology clinics. The standard of care worldwide in clinics is to use multidose eyedrop bottles — meaning there is enough medicine one bottle to treat many patients. hospital upwards of $240,000 over 5 years. 3 “Each U.S.

Medical 52
article thumbnail

Baby Formula Shortages

Georgetown Pediatrics & Family Medicine

Current shortages have been largely caused by supply chain issues and the recent recall of several baby formula products over concerns about contamination. They may have samples in stock, connections to other local organizations, or ideas of other places to call, such as your local WIC clinic. Can I make my own baby formula?

article thumbnail

Does the Drug Shortage White Paper Fall Short?

FDA Law

Department of Health and Human Services (HHS) recently published a White Paper on Policy Considerations to Prevent Drug Shortages and Mitigate Supply Chain Vulnerabilities in the United States —with input from several HHS stakeholders, including FDA, CMS, and the Administration for Strategic Preparedness and Response.

article thumbnail

Drug Pricing Reform Gathers Steam (Part 1): White House Drug Pricing Plan Offers Laundry List of Existing Democrat Priorities

FDA Law

A final OIG rule to change the structure of manufacturer rebates to Medicare Part D and Medicaid Managed Care plans and their PBMs is enmeshed in litigation and is likely to be at least postponed until 2026 (see our post ), and perhaps prevented from implementation altogether, by Congressional mandate.